A 68-year-old man with ischaemic cardiomyopathy has an ejection fraction of 30% and NYHA class II symptoms despite optimal doses of an ACE inhibitor and beta blocker. His blood pressure is 120/70 mmHg and renal function is stable. According to contemporary heart failure guidelines, which additional class of medication should now be added to reduce mortality and hospitalisations?